COVID-19, Research & Technology

Spectrum Health Enrolling Patients in Clinical Trial for Inpatient COVID-19 Treatment

Regeneron’s drug REGN-COV2 has shown improved symptoms in non-hospitalized COVID-19 patients.

GRAND RAPIDS Mich., Oct. 29, 2020 – Spectrum Health is partnering with Regeneron Pharmaceuticals to enroll patients into a clinical trial evaluating REGN-COV2, the company’s investigational antibody cocktail for the treatment and prevention of COVID-19.

Spectrum Health is the only health system in West Michigan and one of only two in the state to offer this trial, known as the aSPIKE trial, for hospitalized COVID-19 patients.

“Spectrum Health is participating in a trial to test the drug’s efficacy in hospitalized patients,” said Spectrum Health Research Physician Gordana Simeunovic, MD. “It is a randomized, double-blind trial that measures the effect of adding the drug to the usual standard-of-care treatment we use in our hospital, compared to adding a placebo.”

The trial is actively enrolling patients hospitalized at Spectrum Health Butterworth Hospital in Grand Rapids. To learn more, please contact covid19research@spectrumhealth.org

In addition to the trial in non-hospitalized patients, REGN-COV2 is currently being studied in a Phase 2/3 clinical trial for the treatment of COVID-19 in hospitalized patients, the Phase 3 open-label RECOVERY trial of hospitalized patients in the UK and a Phase 3 trial for the prevention of COVID-19 in household contacts of infected individuals.

Regeneron confirmed that President Trump received a dose of the company’s investigational COVID-19 antibody treatment, REGN-COV2, following a ‘compassionate use’ request from the President’s physicians.

For more information and data about the trial, please visit Regeneron.

 

###

People are at the heart of everything we do, and the inspiration for our legacy of outstanding outcomes, innovation, strong community partnerships, philanthropy and transparency. Corewell Health is a not-for-profit health system that provides health care and coverage with an exceptional team of 60,000+ dedicated people—including more than 11,500 physicians and advanced practice providers and more than 15,000 nurses providing care and services in 21 hospitals, 300+ outpatient locations and several post-acute facilities—and Priority Health, a provider-sponsored health plan serving more than 1.3 million members. Through experience and collaboration, we are reimagining a better, more equitable model of health and wellness. For more information, visit corewellhealth.org.

Contact:
Tim Hawkins
Media Relations
Office: 616.486.6091
Mobile: 616.443.0361
Email: timothy.hawkins@corewellhealth.org